MONTVALE, N.J., Nov. 21 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its shareholders overwhelmingly approved the proposals submitted to them relating to the acquisition of Barr by Teva Pharmaceuticals Industries Ltd. (Nasdaq: TEVA).
'Today's vote demonstrated the overwhelming support of the transaction by the Barr shareholders,' said Bruce L. Downey, Barr's Chairman and CEO. 'We are pleased with the progress that we continue to make towards completion of the acquisition of Barr by Teva, and we and Teva continue to anticipate completing this transaction prior to the end of the year and combining our two strong organizations.'
About Barr Pharmaceuticals, Inc.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit www.barrlabs.com.
Forward-Looking Statements
This communication contains 'forward-looking statements' which represent the current expectations and beliefs of management of Barr Pharmaceuticals, Inc. (the 'Company') concerning the proposed merger of the Company (the 'merger') with Boron Acquisition Corp., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. (the 'Teva') and other future events and their potential effects on the Company. The statements, analyses, and other information contained herein relating to the proposed merger, as well as other statements including words such as 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'will,' 'should,' 'may,' and other similar expressions, are 'forward-looking statements' under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of future results and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated.
